首页> 美国卫生研究院文献>The Oncologist >Trastuzumab in Human Epidermal Growth Factor Receptor 2‐Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany

【2h】

Trastuzumab in Human Epidermal Growth Factor Receptor 2‐Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany

机译：人类表皮生长因子受体2阳性早期乳腺癌中的曲妥珠单抗：2006年至2012年德国常规治疗的前瞻性，非干预性研究的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Purpose.Trastuzumab is part of the standard treatment in patients with human epidermal growth factor receptor 2‐positive early breast cancer in addition to (neo)adjuvant chemotherapy. This German prospective noninterventional study, which included major patient cohorts underrepresented in the pivotal randomized studies, examined the generalizability of the results of those studies.

机译：目的：除了（新）辅助化疗外，曲妥珠单抗是人类表皮生长因子受体2阳性早期乳腺癌患者标准治疗的一部分。这项德国前瞻性非干预性研究包括了关键随机研究中代表性不足的主要患者队列，研究了这些研究结果的推广性。

著录项

期刊名称 The Oncologist
作者
Peter Dall; *; Thorsten Koch; Thomas Göhler; Johannes Selbach; Andreas Ammon; Jochen Eggert; Nidal Gazawi; Daniela Rezek; Arthur Wischnik; Carsten Hielscher; Stella Keitel; Ursula Cirrincione; Axel Hinke; Gabriele Feisel‐Schwickardi;
展开▼
作者单位

展开▼
年(卷),期 1930(22),2
年度 1930
页码 131–138
总页数 8
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
breast cancer, human epidermal growth factor receptor 2, trastuzumab, adjuvant chemotherapy, observational study;

机译：乳腺癌;人类表皮生长因子受体2;曲妥珠单抗;辅助化疗;观察性研究;

相似文献

外文文献
中文文献
专利

1. Trastuzumab in Human Epidermal Growth Factor Receptor 2a??Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany [J] . Peter Dall, Thorsten Koch, Thomas G??hler, The oncologist . 2017,第2期

机译：人表皮生长因子受体2a中曲妥珠单抗的阳性早期乳腺癌：2006年至2012年德国常规治疗的前瞻性，非干预性研究的结果
2. Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany [J] . Dall Peter, Koch Thorsten, Goehler Thomas, The oncologist . 2017,第2期

机译：人体表皮生长因子受体2阳性早期乳腺癌的曲妥珠单抗：2006年至2012年在德国2006年至2012年期间常规治疗的前瞻性常规研究结果
3. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2-and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) [J] . Harbeck Nadia, Gluz Oleg, Christgen Matthias, Journal of Clinical Oncology . 2017,第26期

机译：人表皮生长因子受体2（HER2） - 阳性早期乳腺癌（BC）的脱升升级策略：对西德语研究组的最终分析辅助动态标记调整的个性化治疗试验优化BC HER2早期风险评估和治疗反应预测 - 激素受体阳性期II II型随机试验 - 疗效，安全性和预测标记为12周的Neoadjuvant Trastuzumab Omtansine，或没有内分泌治疗（ET）
4. Identification of Human Epidermal Growth Factor Receptor 2 Antagonist In Silico for Breast Cancer Therapy, Derived from Indonesian Phytochemicals [C] . Tuti Ratnasari, Dono indarto, Raden Ajeng Sri Wulandari, International Conference on Biomedical Engineering . 2018

机译：人类表皮生长因子受体2拮抗剂在二氧化硅中用于印尼治疗的印尼植物化学成分的鉴定。
5. Indirect Costs Associated with Human Epidermal Growth Factor Receptor Positive (HER2+) Metastatic Breast Cancer [D] . Wright, Phoebe. 2020

机译：与人表皮生长因子受体阳性（HER2 +）转移性乳腺癌相关的间接成本
6. Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II single-arm multicenter study [O] . Shannon Puhalla, Sharon Wilks, Adam M Brufsky, 2016

机译：先前的曲妥珠单抗联合甲磺酸埃里布林联合曲妥珠单抗作为人表皮生长因子受体2阳性局部复发或转移性乳腺癌的一线治疗的临床效果：II期单臂多中心研究的结果
7. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results From the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial [O] . Piccart-Gebhart, Martine, Pritchard, Kathleen, McCullough, Ann A.E., 2016

机译：辅助拉帕替尼和曲妥珠单抗治疗早期人类表皮生长因子受体2阳性乳腺癌：结果来自随机III期拉帕替尼和/或曲妥珠单抗治疗优化试验

Trastuzumab in Human Epidermal Growth Factor Receptor 2‐Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅